Celgene: Psoriasis med improves quality-of-life measures

Celgene Corporation announced the results of two post hoc sub-analyses of clinical trials for OTEZLA at the 27th European Academy of Dermatology and Venereology Congress in Paris, France. Findings suggest OTEZLA offered meaningful improvements in outcomes important to patients with moderate to severe plaque psoriasis, which may not be captured by common measures of treatment efficacy that focus only on skin clearance, such as Psoriasis Area Severity Index 75. The findings include a new post hoc sub-analysis of the phase 3 ESTEEM 1 trial assessing clinical and quality-of-life outcomes for patients with moderate to severe plaque psoriasis who did not achieve PASI 75 at either weeks 32 or 52, but continued OTEZLA treatment in this time period. For patients who did not achieve a PASI 75 at weeks 32 or 52, more than half achieved a 50 percent reduction in PASI score at weeks 32 and 52 following treatment with OTEZLA. This improvement, when taken together in disease-specific quality-of-life measures, may more reliably indicate clinically meaningful benefit. For example, itching, as measured by Visual Analogue Scale, was reduced from baseline by approximately 30 percent during weeks 4 to 52 in those patients who were treated with OTEZLA from baseline and weeks 20 to 52 in patients who were switched from placebo to OTEZLA at week 16. Quality of life, as measured by the Dermatology Life Quality Index, was improved by at least 5 points in the two groups during the same time period. Manifestations that are highly visible, such as scalp and nail psoriasis, can have a substantial effect on quality of life. A separate post hoc sub-analysis of the ESTEEM 1, 2 and UNVEIL studies examined changes in scalp and nail psoriasis, along with quality of life, following treatment with OTEZLA. The sub-analysis included patients who had nail psoriasis or moderate to very severe scalp psoriasis at baseline. At week 32 in ESTEEM and UNVEIL, clearance of nail psoriasis among patients receiving OTEZLA from baseline was achieved by 31.3 percent and 36.2 percent of patients, respectively. Among patients who were switched from placebo to OTEZLA at week 16, NAPSI clearance at week 32 was achieved by 15.5 percent and 26.1 percent of patients, respectively. Among patients with moderate to severe scalp psoriasis at baseline, clear or minimal involvement of scalp psoriasis was achieved by greater proportions of patients receiving OTEZLA versus placebo at week 16 in both trials: 45.2 percent versus 22.5 percent, respectively, in ESTEEM and 44.1 percent versus 33.3 percent in UNVEIL. Of patients who had nail psoriasis or moderate to very severe scalp psoriasis at baseline, a DLQI of 0 or 1 was achieved by greater proportions of patients receiving OTEZLA versus placebo at week 16.
https://thefly.com/landingPageNews.php?id=2789105